Frozen Shoulder Treatment Market By Treatment Type (Physical Therapy and Rehabilitation, Corticosteroid Injections, Hydrodilatation, Pain Management Medications, Suprascapular Nerve Blocks, Manipulation Under Anesthesia, Arthroscopic Capsular Release, Transarterial Embolization); By Application (Primary Frozen Shoulder, Diabetes-Associated Frozen Shoulder, Post-Surgical Frozen Shoulder, Post-Traumatic Frozen Shoulder, Refractory Frozen Shoulder); By End User (Hospitals, Orthopedic Clinics, Physiotherapy and Rehabilitation Centers, Sports Medicine Clinics, Diagnostic and Interventional Radiology Centers, Ambulatory Surgical Centers, Pain Management Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Frozen Shoulder Treatment Market: Injection-Led Care and Hydrodilatation Keep Surgery Selective

The Global Frozen Shoulder Treatment Market was valued at USD 1.28 billion in 2025 and is projected to reach USD 1.99 billion by 2032, growing at a CAGR of 6.5%, according to Strategic Market Research.

 

Most frozen shoulder treatment spending is concentrated in physical therapy, corticosteroid injections, pain relief, and outpatient care. Surgery is generally reserved for patients with persistent pain and restricted movement after several months of conservative treatment.

 

Corticosteroid injections serve as the primary pharmacological approach due to their ability to deliver relatively quick pain relief at a minimal cost. Physical therapy accounts for the highest volume of services, while hydrodilatation is positioned between a standard injection and more invasive procedures such as manipulation or arthroscopic release. Treatments like transarterial embolization, perineural dextrose injection, and fibrosis-targeted therapies are still under investigation and have not yet become recognized revenue streams.

 

Diabetes serves as the most definitive long-term predictor of treatment demand. Individuals with diabetes are more likely to develop frozen shoulder, and their symptoms tend to be more persistent and challenging to manage. The increasing prevalence of diabetes is expected to elevate the number of adults who may need injections, extended rehabilitation, hydrodilatation, or interventions for resistant cases.

 

Diabetes Expands the High-Risk Patient Pool

Frozen shoulder affects an estimated 2% to 5% of the general population. It is most often diagnosed between 40 and 60 years of age and occurs slightly more often in women.

Reported prevalence varies because studies use different diagnostic criteria, referral settings, and measures of confirmed disease or self-reported stiffness. Country-level treatment demand is better assessed through orthopedic consultations, insurance claims, rehabilitation activity, and procedure volumes than by applying a single prevalence estimate across all markets.

A meta-analysis estimated frozen shoulder prevalence at 13.4% among people with diabetes and found that diabetic patients were about five times more likely to develop the condition than people without diabetes. Approximately 30% of frozen shoulder patients in the reviewed studies also had diabetes.

The International Diabetes Federation estimated that 589 million adults aged 20–79 were living with diabetes in 2024, equivalent to one in nine adults. The total is projected to reach 853 million by 2050. More than 80% of adults with diabetes live in low- and middle-income countries, where specialist rehabilitation and image-guided interventions are often less accessible.

Diabetes also changes treatment decisions. Higher corticosteroid doses may provide additional short-term functional improvement, but a 2025 clinical guideline reported higher blood glucose at six weeks in patients receiving a high-dose injection than in those receiving a lower dose. Orthopedic physicians and rehabilitation specialists must balance pain relief against glycemic effects, particularly in patients with poorly controlled diabetes or repeat injection requirements.

Thyroid disease and dyslipidemia are also associated with primary frozen shoulder, but diabetes has greater importance for treatment planning because of its prevalence, documented risk relationship, and effect on recovery. Diabetic patients are more likely to generate repeat visits, longer therapy courses, and escalation beyond a basic home-exercise programme.

 

Conservative Care Accounts for Most Treatment Activity

More than 90% of patients are managed without surgery, keeping physical therapy, home exercise, anti-inflammatory medication, and corticosteroid injections at the centre of routine care. Surgeons generally reserve manipulation and arthroscopic release for patients who continue to have severe pain and stiffness after an extended period of nonoperative treatment.

Physical therapy revenue depends on treatment frequency and duration rather than expensive medicines or equipment. Patients may need supervised mobilisation, stretching, range-of-motion exercises, education, and a structured home programme over several weeks.

A 2025 guideline supported manual therapy and range-of-motion exercises for improving upper-limb function and shoulder movement, although the underlying evidence remained low quality and protocols differed considerably. Clinics therefore compete through therapist experience, exercise selection, treatment frequency, and coordination with injections rather than through one standardised rehabilitation programme.

A 2025 randomized trial assigned 48 patients to either an intra-articular corticosteroid injection or a defined multimodal physiotherapy programme, with both groups also completing home exercises. Pain, disability, and range of motion improved in both groups over six weeks. Multimodal physiotherapy produced stronger effects in patient-reported function and internal rotation, although most differences between the groups were not statistically significant.

Structured rehabilitation can therefore provide a credible alternative to injection, but the result does not imply that all physical therapy programmes perform equally. Provider training, mobilisation technique, exercise intensity, appointment frequency, and patient adherence influence outcomes and create substantial variation across clinics.

Home exercise reduces treatment cost but shifts responsibility to the patient. The 2025 guideline found no direct evidence that self-stretching alone was superior to control treatment, although observational evidence linked daily stretching with better movement and shorter recovery when patients received appropriate instruction.

Rehabilitation providers can improve adherence by combining in-person assessment with clear exercise plans, movement targets, and follow-up monitoring. Digital rehabilitation platforms may support this process through reminders, video guidance, and remote range-of-motion tracking.

Generic exercise libraries are unlikely to replace therapist-led care because pain severity, disease stage, movement restriction, and compensatory motion vary by patient. Digital tools are better positioned as an extension of supervised rehabilitation than as a stand-alone frozen shoulder treatment.

 

Corticosteroid Injections Lead Early Procedural Care

Intra-articular corticosteroid injections remain the most established procedure for patients who need faster pain relief than exercise alone can provide. A 2025 evidence-based guideline reviewed 21 randomized trials and recommended steroid injections for improving pain and upper-limb function.

Combining an injection with physical therapy produced better short- and medium-term pain and functional outcomes than physical therapy alone. Orthopedic and sports-medicine clinics can therefore use injections to reduce pain sufficiently for patients to participate more effectively in rehabilitation.

Steroid injections have their greatest value during the painful inflammatory phase, when sleep disruption and movement-related pain prevent effective stretching. Short-term relief may allow patients to regain motion before capsular stiffness becomes more established.

Benefits tend to weaken over the full natural course of the condition, so clinicians generally use injections as one part of a multimodal pathway rather than as a stand-alone cure. Patients may still require supervised exercise, home stretching, and further intervention if restriction persists.

Ultrasound guidance improves needle-placement accuracy but has not produced a clear advantage in pain or functional recovery when experienced clinicians perform the injection. The 2025 guideline found only a 2.63-degree short-term improvement in external rotation with ultrasound guidance and no significant advantage in pain or upper-limb function.

Clinics may still use ultrasound to confirm placement, document the procedure, support patient confidence, and reduce uncertainty among less-experienced injectors. Revenue from imaging-guided injection therefore depends partly on workflow, documentation, and provider preference rather than a large proven clinical advantage.

Steroid dose also varies. Trials comparing 40 mg and 20 mg of triamcinolone found no significant difference in pain relief, although the higher dose produced some short-term gains in function, abduction, and external rotation.

Diabetes, facial flushing, and blood-glucose elevation may lead clinicians to select lower doses or monitor patients more closely. Practices treating a large diabetic population may need tighter coordination with primary-care physicians or endocrinologists when repeat injections are considered.

Suprascapular nerve blocks provide another outpatient pain-control option, particularly when severe pain prevents therapy participation or when steroid exposure is less desirable. Guideline support remains conditional because the evidence base is smaller and less consistent than that for intra-articular corticosteroids.

 

Hydrodilatation Fills the Gap Between Injection and Surgery

Hydrodilatation gives orthopedic, sports-medicine, rehabilitation, and radiology providers an intermediate treatment for patients who do not improve adequately with medication, exercise, or a standard injection. The procedure combines an intra-articular injection with a larger fluid volume to stretch the contracted capsule.

A 2023 systematic review found that hydrodilatation produced early improvements in disability and short- and long-term gains in passive external rotation. Most long-term outcomes were comparable with intra-articular corticosteroid injection, and pooled comparisons did not establish clear superiority over manipulation, arthroscopic release, or general physiotherapy.

A 2025 clinical guideline reached a somewhat more favourable conclusion after reviewing nine studies. Hydrodilatation combined with corticosteroid produced modestly greater short- and medium-term pain relief and functional improvement than corticosteroid injection alone. Small study populations and differences between protocols kept the recommendation conditional.

Outpatient delivery and avoidance of general anaesthesia give hydrodilatation a lower procedural burden than surgery. The procedure can also be integrated with radiology, orthopedic, and rehabilitation services within the same care pathway.

Lack of standardisation limits wider adoption. Providers use different injectate volumes, capsular rupture techniques, imaging methods, steroid doses, local anaesthetics, and post-procedure rehabilitation protocols.

Hospitals and imaging centres can improve consistency by standardising technique and arranging rehabilitation soon after the procedure. Payers may still question premium reimbursement when long-term outcomes remain similar to those of a lower-cost corticosteroid injection.

The UK Adhesive Capsulitis Corticosteroid and Dilation feasibility programme is comparing corticosteroid injection with hydrodilatation against corticosteroid injection alone. Larger multicentre evidence could determine whether hydrodilatation becomes a routine second-line treatment or continues to depend on local physician preference.

 

Surgery Produces High Per-Patient Revenue in Refractory Cases

Manipulation under anaesthesia and arthroscopic capsular release are reserved for persistent disease because both require more resources and carry greater risk than rehabilitation or injection. The eligible population is much smaller than the total diagnosed population, but each case generates operating-room, anaesthesia, imaging, surgical-device, and postoperative therapy revenue.

UK FROST provides the strongest comparative evidence for secondary-care treatment. The trial randomized 503 patients across 35 UK hospitals to manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy that included a steroid injection and up to 12 weekly sessions.

Shoulder function improved in all three groups. Arthroscopic release produced statistically better scores at 12 months, but the differences were not considered clinically important.

All ten serious adverse events occurred in the surgical groups: eight after allocation to arthroscopic release and two after manipulation. Early structured physiotherapy carried lower procedural risk but produced a greater likelihood of additional treatment.

Arthroscopic release cost an average of £1,733.78 more per patient than early structured physiotherapy and produced an incremental cost-effectiveness ratio above £100,000 per additional quality-adjusted life year.

Manipulation under anaesthesia cost £276 more than physiotherapy and produced an incremental cost-effectiveness ratio of £6,984 per quality-adjusted life year. Under the trial assumptions, manipulation was the most likely cost-effective option among the three pathways.

Hospitals have limited economic justification for moving patients directly to arthroscopic release when structured physiotherapy and injections remain available. Arthroscopy retains a role when surgeons or patients value a more definitive release, lower retreatment risk, or concurrent intra-articular assessment.

Manipulation occupies a lower-cost surgical position but carries risks that include fracture and rotator cuff injury. The 2025 guideline recommended corticosteroid injection before manipulation because evidence of clinical superiority remains insufficient.

 

Embolization Could Create a New Interventional Radiology Service

Transarterial embolization is the most advanced emerging procedure for refractory frozen shoulder. Interventional radiologists deliver embolic material into abnormal periarticular vessels associated with inflammation and pain, targeting vascular activity rather than mechanically releasing the capsule.

A 2025 study followed 25 patients whose adhesive capsulitis had not improved with conservative treatment. Pain, disability, flexion, and abduction improved at one, three, and six months after embolization. MRI also showed reduced inflammatory findings in the capsule and rotator interval.

The small retrospective cohort does not support direct comparison with hydrodilatation, manipulation, or surgery. A 2025 systematic review also reported large pooled improvements in pain, movement, and shoulder function but identified uncontrolled study designs, short follow-up, and substantial heterogeneity.

Current evidence supports continued clinical evaluation rather than routine reimbursement. A prospective randomized trial registered in January 2026 is evaluating Nexsphere-F embolic particles in patients who have not responded to conservative treatment.

Positive randomized results could create demand for embolic agents, microcatheters, angiography capacity, and interventional-radiology training. Hospitals with existing musculoskeletal embolization programmes would be better positioned to adopt the procedure than general orthopedic clinics.

Embolization must still demonstrate enough benefit to justify a catheter-based intervention for a condition usually treated without surgery. Comparative cost, radiation exposure, embolic-material regulation, durability, and access to trained interventionalists will determine whether use remains concentrated in specialist centres.

 

Targeted Drug Development Remains Limited

Low-cost generic medicines and local procedures dominate frozen shoulder treatment, leaving little room for premium pharmaceutical pricing. No targeted antifibrotic medicine has established a regulatory pathway comparable with therapies developed for chronic inflammatory or fibrotic diseases.

Endo evaluated collagenase clostridium histolyticum, the active ingredient in Xiaflex, as a local treatment intended to break down contracted capsular collagen. The Phase II study failed to produce a statistically significant improvement over placebo in its primary pain-and-function endpoint at day 95.

Collagenase therefore remains a failed proof-of-concept programme rather than a near-term commercial product. Any future enzymatic treatment would need to demonstrate reliable capsular targeting, meaningful functional improvement, and acceptable local safety.

Tetrandrine has produced anti-inflammatory, anti-angiogenic, and antifibrotic effects in a rat frozen shoulder model. The absence of human clinical evidence prevents its inclusion in current treatment forecasts.

Perineural injection therapy with low-concentration dextrose has moved into human testing. A registered study is assessing whether injections near superficial nerves can improve pain and range of motion when added to conventional care.

The programme remains exploratory and has not established dosing, durability, comparative effectiveness, or reimbursement value. Early improvement in movement would need to translate into a shorter treatment course or lower use of injections and surgery before payers view the therapy as economically relevant.

Research published in 2026 identified macrophage activity, CCL2/CCR2 signalling, mechanical stress, and fibroblast interaction as contributors to the transition from inflammation to fibrosis. The findings may support local inhibitors, sustained-release depots, or biomaterial carriers, but no late-stage therapeutic asset has emerged.

 

Regional Spending Depends on Access to Procedures and Rehabilitation

North America supports high outpatient spending through orthopedic practices, sports-medicine centres, rehabilitation networks, ultrasound-guided injection services, and ambulatory surgery centres. Conservative care remains dominant, while insurance design and therapy copayments influence how many supervised rehabilitation sessions patients complete.

The UK provides the clearest health-economic evidence because UK FROST directly compared structured physiotherapy, manipulation, and arthroscopic release. NHS providers are likely to favour lower-cost pathways unless surgery reduces retreatment enough to justify its higher initial expense.

Hydrodilatation could gain a stronger NHS role if multicentre evidence demonstrates a consistent advantage over corticosteroid injection alone. Without that evidence, use will continue to vary by hospital, radiology department, and physician preference.

Asia-Pacific has a large diabetes-linked risk population. The International Diabetes Federation estimates 107 million adults with diabetes in South-East Asia and 215 million in the Western Pacific.

Rising case volume will increase demand for physical therapy, injections, orthopedic consultation, and pain services. Affordability and specialist capacity will determine how many patients progress to image-guided procedures or surgery.

India alone had an estimated 89.8 million adults with diabetes in 2024. Even a modest diagnosed frozen shoulder rate creates a large treatment population, although care remains divided among formal physiotherapy, orthopedic clinics, pain centres, and lower-cost community providers.

 

Provider Positioning Depends on Coordinated Care

Physical therapy providers retain the largest patient-volume position because rehabilitation remains central during early treatment, after injections, and following procedures. Clinics with stage-specific protocols, adherence monitoring, and direct referral relationships with orthopedic physicians are better positioned than providers offering generic shoulder exercises.

Orthopedic and sports-medicine clinics capture more revenue per patient through consultation, corticosteroid injection, ultrasound guidance, and escalation management. Practices that coordinate injection timing with immediate rehabilitation can retain patients across more of the treatment pathway.

Radiology providers benefit from hydrodilatation and could develop an additional service line through transarterial embolization. Adoption will favour centres with musculoskeletal imaging expertise, procedural infrastructure, and established referral networks.

Ambulatory surgical centres and hospitals serve the smaller refractory population requiring manipulation or arthroscopic release. Their growth depends less on overall prevalence than on conservative-treatment failure, referral patterns, and payer approval.

Drug manufacturers have limited pricing power because NSAIDs, corticosteroids, and local anaesthetics are mature generic products. A branded therapy would need to shorten recovery, prevent capsular fibrosis, or reduce repeat procedures without introducing substantial systemic risk.

Frozen shoulder treatment will remain service- and procedure-led unless a targeted antifibrotic therapy succeeds in controlled clinical trials. Diabetes-linked case growth, earlier corticosteroid use, structured rehabilitation, wider hydrodilatation adoption, and selective embolization in refractory disease will account for most near-term expansion.

Providers that coordinate injections, rehabilitation, imaging, and escalation within one treatment pathway are likely to capture more patient value than clinics offering isolated sessions or procedures.

 

Frozen Shoulder Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.28 Billion
Revenue Forecast in 2032	USD 1.99 Billion
Overall Growth Rate	CAGR of 6.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Physical Therapy and Rehabilitation, Corticosteroid Injections, Hydrodilatation, Pain Management Medications, Suprascapular Nerve Blocks, Manipulation Under Anesthesia, Arthroscopic Capsular Release, Transarterial Embolization
By Application	Primary Frozen Shoulder, Diabetes-Associated Frozen Shoulder, Post-Surgical Frozen Shoulder, Post-Traumatic Frozen Shoulder, Refractory Frozen Shoulder
By End User	Hospitals, Orthopedic Clinics, Physiotherapy and Rehabilitation Centers, Sports Medicine Clinics, Diagnostic and Interventional Radiology Centers, Ambulatory Surgical Centers, Pain Management Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising prevalence of frozen shoulder linked with diabetes, aging populations, and post-surgical recovery needs. • Growing adoption of minimally invasive treatment approaches, including image-guided interventions and advanced rehabilitation protocols. • Increasing focus on pain management solutions and improved access to orthopedic and physiotherapy services.
Customization Option	Available upon request